Skip to main content
SpringerLink
Log in

Anti-Interleukin-5-Therapie bei eosinophilen Erkrankungen

Anti-interlekuin-5 therapy for eosinophilic diseases

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Bei einer Reihe von Erkrankungen, die durch eine Eosinophilie charakterisiert sind, findet man erhöhte Spiegel von Interleukin- (IL-)5 im Blut und/oder Gewebe. IL-5 spielt eine wichtige Rolle in der Regulierung von Produktion, Differenzierung, Rekrutierung, Aktivierung und Überleben eosinophiler Granulozyten. Daher stellt die Neutralisation von IL-5 durch blockierende Antikörper einen vielversprechenden neuen Ansatz in der Therapie dieser Erkrankungen dar. Erste klinische Studien zeigten, dass es nach Applikation von Anti-IL-5-Antikörpern zu einem raschen Abfall der Eosinophilenzahlen im peripheren Blut kommt. Eine Abnahme der Beschwerden wurde bei der lymphozytären Form hypereosinophiler Syndrome, bei eosinophiler Ösophagitis und bei chronischer Rhinitis mit nasaler Polyposis beobachtet. Im Gegensatz dazu zeigte eine Anti-IL-5-Antikörper-Behandlung von Patienten mit Asthma bronchiale oder mit atopischem Ekzem nicht den erwarteten klinischen Effekt. Zukünftige Studien werden zeigen, bei welchen eosinophilen Erkrankungen eine Anti-IL-5-Therapie wirksam ist und welche Patientengruppen auf diese Therapie ansprechen.

Abstract

In a number of diseases with eosinophilia, elevated interleukin (IL)-5 levels are detected in the peripheral blood and/or tissues. IL-5 plays an important role in regulating the production, differentiation, recruitment, activation, and survival of eosinophils. Therefore, neutralizing IL-5 by blocking antibodies seems a promising approach in the treatment of eosinophilic diseases. Clinical trials have demonstrated that anti-IL-5 therapy results in a rapid decrease in peripheral blood eosinophil numbers. Moreover, improvement of symptoms in patients with lymphocytic variants of hypereosinophilic syndromes, in eosinophilic esophagitis and chronic rhinitis with nasal polyposis has been observed. In contrast, in patients with bronchial asthma or atopic eczema, anti-IL-5 therapy showed only moderate or no clinical effects. Future studies will have to identify those eosinophilic diseases in which anti-IL-5 antibodies are effective, perhaps with the help of newly developed biomarkers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Akdis CA, Akdis M, Simon D et al. (1999) T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol 113: 628–634

    Article  PubMed  Google Scholar 

  2. Arora AS, Yamazaki K (2004) Eosinophilic esophagitis: asthma of the esophagus. Clin Gastroenterol Hepatol 2: 523–530

    Article  PubMed  Google Scholar 

  3. Buttner C, Lun A, Splettstoesser T et al. (2003) Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 21: 799–803

    Article  PubMed  Google Scholar 

  4. Cheng JF, Ott NL, Peterson EA et al. (1997) Dermal eosinophils undergo cytolytic degeneration. J Allergy Clin Immunol 99: 683–692

    Article  PubMed  Google Scholar 

  5. Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54: 1–27

  6. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS (2003) Eosinophil’s role remains uncertain as anti-IL-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167: 199–204

    Article  PubMed  Google Scholar 

  7. Garrett JK, Jameson SC, Thomson B et al. (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113: 115–119

    Article  PubMed  Google Scholar 

  8. Geveart P, Lang-Loidolt D, Lackner A et al. (2006) Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118: 1133–1141

    Article  PubMed  Google Scholar 

  9. Gleich GJ (2000) Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105: 651–663

    Article  PubMed  Google Scholar 

  10. Gregory B, Kirchem A, Phipps S et al. (2003) Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor α-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor α expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor α expression. J Immunol 170: 5359–5366

    PubMed  Google Scholar 

  11. Hamelman E, Gelfand EW (2001) IL-5-induced airway eosinophilia-the key to asthma? Immunol Rev 179: 182–191

    Article  PubMed  Google Scholar 

  12. Hart TK, Cook RM, Zia-Amirhosseini P et al. (2001) Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 108: 250–257

    Article  PubMed  Google Scholar 

  13. Kiehl P, Falkenberg K, Vogelbruch M, Kapp A (2001) Tissue eosinophilia in acute and chronic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol 145: 720–729

    Article  PubMed  Google Scholar 

  14. Kips JC, O’Connor BJ, Langley SJ et al. (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistant asthma: a pilot study. Am J Respir Crit Care Med 167: 1655–1659

    Article  PubMed  Google Scholar 

  15. Klion A, Nutman TB (2004) The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 113: 30–37

    Article  PubMed  Google Scholar 

  16. Leckie MJ, ten Brinke A, Khan J et al. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144–2148

    Article  PubMed  Google Scholar 

  17. Leifermann KM, Ackermann SJ, Sampson HA et al. (1985) Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis. N Engl J Med 313: 282–285

    PubMed  Google Scholar 

  18. Mattes J, Yang M, Mahalingam S et al. (2002) Intrinsic defect in T cell production of interleukin (IL)-13 in the abscence of both IL-5 and eotaxin precludes the development of eosinophilia and airway hyperreactivity in experimental asthma. J Exp Med 195: 1433–1444

    Article  PubMed  Google Scholar 

  19. Menzies-Gow A, Flood-Page P, Sehmai R et al. (2003) Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 111: 714–719

    Article  PubMed  Google Scholar 

  20. Mishra A, Rothenberg ME (2003) Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent manner. Gastroenterology 125: 1419–1427

    Article  PubMed  Google Scholar 

  21. Oldhoff JM, Darsow U, Werfel T et al. (2005) Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis. Allergy 60: 693–696

    Article  PubMed  Google Scholar 

  22. Phipps S, Flood-Page P, Menzies-Gow A et al. (2004) Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 122: 1406–1412

    Article  PubMed  Google Scholar 

  23. Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J (2003) Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349:2332–2337.

    Google Scholar 

  24. Simon D, Braathen LR, Simon HU (2004) Eosinophils and atopic dermatitis. Allergy 59: 561–570

    Article  PubMed  Google Scholar 

  25. Simon D, Vassina E, Yousefi S et al. (2004) Reduced dermal infiltration of cytokine-expressing cells in atopic dermatitis following short-term topical tacrolimus treatment. J Allergy Clin Immunol 114: 887–895

    Article  PubMed  Google Scholar 

  26. Simon D, Vassina E, Yousefi S et al. (2005) Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 60: 944–951

    Article  PubMed  Google Scholar 

  27. Simon D, Marti H, Heer P et al. (2005) Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases. J Allergy Clin Immunol 115: 1090–1092

    Article  PubMed  Google Scholar 

  28. Simon HU (1998) Eosinophil apoptosis in allergic diseases – an emerging new issue. Clin Exp Allergy 28: 1321–1324

    Article  PubMed  Google Scholar 

  29. Simon HU, Plötz SG, Dummer R, Blaser K (1999) Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341: 1112–1120

    Article  PubMed  Google Scholar 

  30. Straumann A, Bauer M, Fischer B et al. (2001) Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 108: 954–961

    Article  PubMed  Google Scholar 

  31. Straumann A, Spichtin HP, Grize L et al. (2003) Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 125: 1660–1669

    Article  PubMed  Google Scholar 

  32. Straumann A, Simon HU (2004) The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Allergy 59: 15–25

    Article  PubMed  Google Scholar 

  33. Wang J, Palmer K, Lötvall J et al. (1998) Circulating, but not local lung, IL-5 is required for the development of antigen-induced airway eosinophilia. J Clin Invest 102: 1132–1141

    PubMed  Google Scholar 

  34. Zhang J, Kuvelkar R, Murgolo NJ et al. (1999) Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol 11: 1935–1944

    Article  PubMed  Google Scholar 

Download references

Danksagung

Die Forschung im Labor von Prof. Dr. med. Hans-Uwe Simon wird vom Schweizerischen Nationalfonds (Gesuch-Nr. 310000-107526), der Stanley Thomas Johnson-Stiftung (Bern) und der OPO-Stiftung (Zürich) unterstützt.

Interessenkonflikt

Keine Angaben.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Venerologie, Inselspital, Universität Bern, 3010, Bern, Schweiz

    D. Simon & L.R. Braathen

  2. Institut für Pharmakologie, Universität Bern, Schweiz, Bern

    H.-U. Simon

Authors
  1. D. Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L.R. Braathen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H.-U. Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Simon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simon, D., Braathen, L. & Simon, HU. Anti-Interleukin-5-Therapie bei eosinophilen Erkrankungen. Hautarzt 58, 122–127 (2007). https://doi.org/10.1007/s00105-006-1273-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-006-1273-x

Schlüsselwörter

Keywords

Search

Navigation